Valion Bio Statistics
Total Valuation
Valion Bio has a market cap or net worth of $3.68 million. The enterprise value is $18.98 million.
| Market Cap | 3.68M |
| Enterprise Value | 18.98M |
Important Dates
The last earnings date was Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Valion Bio has 22.19 million shares outstanding. The number of shares has increased by 297.05% in one year.
| Current Share Class | 22.19M |
| Shares Outstanding | 22.19M |
| Shares Change (YoY) | +297.05% |
| Shares Change (QoQ) | +17.21% |
| Owned by Insiders (%) | 0.63% |
| Owned by Institutions (%) | 5.90% |
| Float | 21.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 4.10.
| Current Ratio | 1.11 |
| Quick Ratio | 0.69 |
| Debt / Equity | 4.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.38 |
Financial Efficiency
Return on equity (ROE) is -459.52% and return on invested capital (ROIC) is -83.36%.
| Return on Equity (ROE) | -459.52% |
| Return on Assets (ROA) | -57.13% |
| Return on Invested Capital (ROIC) | -83.36% |
| Return on Capital Employed (ROCE) | -57.43% |
| Weighted Average Cost of Capital (WACC) | 8.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$369,808 |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.81% in the last 52 weeks. The beta is 1.86, so Valion Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | -94.81% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 33.80 |
| Average Volume (20 Days) | 24,752,787 |
Short Selling Information
The latest short interest is 837,868, so 3.78% of the outstanding shares have been sold short.
| Short Interest | 837,868 |
| Short Previous Month | 263,890 |
| Short % of Shares Out | 3.78% |
| Short % of Float | 3.81% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.90M |
| Pretax Income | -18.23M |
| Net Income | -19.23M |
| EBITDA | -16.54M |
| EBIT | -16.90M |
| Earnings Per Share (EPS) | -$8.41 |
Balance Sheet
The company has $2.11 million in cash and $17.41 million in debt, with a net cash position of -$15.30 million or -$0.69 per share.
| Cash & Cash Equivalents | 2.11M |
| Total Debt | 17.41M |
| Net Cash | -15.30M |
| Net Cash Per Share | -$0.69 |
| Equity (Book Value) | 4.25M |
| Book Value Per Share | 1.02 |
| Working Capital | 336,000 |
Cash Flow
In the last 12 months, operating cash flow was -$14.58 million and capital expenditures -$99,000, giving a free cash flow of -$14.67 million.
| Operating Cash Flow | -14.58M |
| Capital Expenditures | -99,000 |
| Depreciation & Amortization | 365,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -14.67M |
| FCF Per Share | -$0.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Valion Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -297.05% |
| Shareholder Yield | -297.05% |
| Earnings Yield | -547.11% |
| FCF Yield | -417.49% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 7, 2025. It was a reverse split with a ratio of 1:17.
| Last Split Date | Mar 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |